AMENDED CLAIMS

1-10. (Canceled)

11. (Currently amended) A <u>parenteral</u> pharmaceutical composition <u>with injection site</u> <u>toleration</u> comprising a therapeutically effective amount of an Active Pharmaceutical <u>Ingredient</u>, a compound of Formula (la),

or a pharmaceutically acceptable salt thereof, a β -cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.

- 12. (Canceled)
- 13. (Currently amended) The pharmaceutical composition according to Claim [[12]] $\underline{11}$ wherein the β -cyclodextrin is 2-hydroxypropyl- β -cyclodextrin or sulfobutyl ether- β -cyclodextrin.

Attorney Docket No. PC25670A U.S. Patent Appl. No. 10/588,070

- 14. (Currently amended) The pharmaceutical composition according to claim [[12]] 13 wherein the preservative is selected from thimerosal, propylene glycol, phenol, or meta-cresol or a combination thereof.
- 15. (Currently amended) The pharmaceutical composition according to claim 14 wherein the preservative is about 2.5 to about 3.5 mg/mL of meta-cresol, the cyclodextrin is sulfobutyl ether-β-cyclodextrin, and wherein the pharmaceutically acceptable salt is the citrate monohydrate salt.
- 16. (Currently amended) The pharmaceutical composition according to claim 14 wherein the preservative has a binding value to the cyclodextrin that is less than [[a]] the binding value of the Active Pharmaceutical Ingredient compound of Formula (1a) to cyclodextrin.

17-18. (Canceled)

19. (Currently amended) The pharmaceutical composition according to claim 16 wherein the binding value of the Active Pharmaceutical Ingredient compound of Formula (1a) to cyclodextrin is between 800 M⁻¹ and 31,000 3,000 M⁻¹.

20-28. (Canceled)

- 29. (New) A pharmaceutical composition comprising about 10 mg/mL of a compound of Formula (la), about 3.3 mg/mL meta-cresol, about 63 mg/mL sulfobutyl ether-β-cyclodextrin, and a pharmaceutically acceptable vehicle.
- 30. (New) A method for the treatment of emesis in an animal comprising administering to said animal a composition according to Claim 11.